Pfizer Corporation Hong Kong Limited 美國輝瑞科研製藥

Indication¹

In combination with other antiretrovirals, for treatment-experienced adult patients infected with CCR5-tropic HIV-1 detectable.

Clinical Evidence¹

Maraviroc twice daily plus optimized background therapy (OBT) was superior to OBT alone across all subgroups of patients infected with CCR5 tropic HIV-1

Safety Profile¹

CI:	Hypersensitivity to maraviroc, any of the excipients, or to peanut or soya.

SP:	Postural hypotension, active tuberculosis, invasive fungal infections, impaired immune response, severe cardiovascular disease, immune reconstitution syndrome, osteonecrosis, liver disease, hepatitis B or C, renal impairment, pregnancy and lactation.

AR:	Dizziness, paraesthesia, dysgeusia, somnolence. Cough. Nausea, vomiting, abdominal pain, abdominal distension, dyspepsia, constipation. Rash, pruritus. Muscle spasms, back pain. Asthenia. Insomnia. Alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, weight decreased.

DI:	Co-administration with CYP3A inhibitors, including protease inhibitors (PIs) (except tipranavir/ritonavir) and delavirdine, will increase the concentration of maraviroc. Co-administration with CYP3A inducers, including efavirenz, may decrease the concentration of maraviroc.

Dosages¹

150 mg, 300 mg or 600 mg twice daily depending on potential interactions. Please refer to product information for details.

Strengths¹

150 mg, 300 mg.

Packing¹

Film-coated tab 150 mg x 60's. 300 mg x 60's.

References

1. Celsentri™ full prescribing information. Hong Kong. Pfizer; August 2007.

Please review the full product information or package insert before prescribing.